Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Attrition in treatment-resistant depression

predictors and clinical impact

Olgiati, Paoloa; Serretti, Alessandroa; Souery, Danielb; Kasper, Siegfriedc; Kraus, Christophc; Montgomery, Stuartd; Zohar, Josephe; Mendlewicz, Julienf

International Clinical Psychopharmacology: July 2019 - Volume 34 - Issue 4 - p 161–169
doi: 10.1097/YIC.0000000000000261
Original Articles
Buy

The aim of this study was to investigate attrition (dropout) during a second antidepressant trial in treatment-resistant depression. Three hundred forty-two outpatients with major depressive disorder and lack of response to a prior antidepressant were treated with venlafaxine for 6 weeks. Sociodemographic and clinical characteristics were compared between the attrition and non-attrition groups. Attrition was reported in 65 patients (19%), of whom 30 patients (46%) dropped out within week 4. The characteristics of dropout patients included a longer duration of depressive episode (P = 0.011) and lower antidepressant doses (P < 0.0001) as a consequence of a faster decrease (week 2) in depressive symptoms (P = 0.028). However, by controlling for early improvement, dropout subjects were associated with a smaller probability of antidepressant response (odds ratio = 0.16▪.83). A decrease of at least 30% in Montgomery Asberg Depression Rating Scale on day 14 predicted subsequent dropout with high specificity (81.9%▪1.0%) but lower sensitivity (19.6%▪2.8%) for clinical use. Patients who have been depressed for a longer period and show an initial improvement of symptoms after changing their antidepressant may be at increased risk for drop out. Further studies are necessary to ascertain the usefulness of these characteristics for predicting attrition.

aDepartment of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy

bLaboratoire de Psychologie Médicale, Université Libre de Bruxelles, and Centre Européen de Psychologie Médicale-PsyPluriel, Brussels, Belgium

cDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

dImperial College, University of London, London, UK

eChaim Sheba Medical Center, Tel-Hashomer, Israel

fUniversité Libre de Bruxelles, Brussels, Belgium

Received 27 September 2018 Accepted 7 March 2019

Correspondence to Alessandro Serretti, MD, PhD, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy, Tel: +39 051 6584233; fax: +39 051 521030; e-mail: alessandro.serretti@unibo.it

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.